ENTERO Entero Healthcare Solutions Q3 FY26 results (Oct–Dec 2025) and concall
Entero Healthcare Solutions delivered a strong Q3 FY26, with revenue growing 26% YoY and EBITDA up 36% YoY, driven by robust organic growth and strategic MedTech acquisitions. The company demonstrated improved operational efficiency, reflected in better working capital days and positive operating cash flow. Management expressed confidence in achieving full-year guidance for both OCF and EBITDA margins, despite the need for significant Q4 performance.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 25.6%, net profit up 17.2% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 1,301 | 1,359 | 1,339 | 1,404 | 1,571 +21% | 1,707 +26% |
| EBITDA | 42 | 50 | 49 | 50 | 62 +48% | 68 +36% |
| Net profit | 26 | 29 | 31 | 30 | 37 +42% | 34 +17% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
